Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Q-linea

BATS-CHIXE:QLINES
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
QLINES
BATS-CHIXE
SEK1B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • Q-linea has significant price volatility in the past 3 months.
QLINES Share Price and Events
7 Day Returns
3.1%
BATS-CHIXE:QLINES
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-
BATS-CHIXE:QLINES
-0.3%
GB Medical Equipment
-23.6%
GB Market
QLINES Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Q-linea (QLINES) 3.1% -22.6% - - - -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • No trading data on QLINES.
  • No trading data on QLINES.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Q-linea undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Q-linea. This is due to cash flow or dividend data being unavailable. The share price is SEK52.6.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Q-linea's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Q-linea's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:QLINES PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-7.74
OM:QLINEA Share Price ** OM (2020-04-07) in SEK SEK52.8
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Q-linea.

BATS-CHIXE:QLINES PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:QLINEA Share Price ÷ EPS (both in SEK)

= 52.8 ÷ -7.74

-6.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Q-linea is loss making, we can't compare its value to the GB Medical Equipment industry average.
  • Q-linea is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Q-linea's expected growth come at a high price?
Raw Data
BATS-CHIXE:QLINES PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
40.4%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Q-linea, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Q-linea's assets?
Raw Data
BATS-CHIXE:QLINES PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK14.88
OM:QLINEA Share Price * OM (2020-04-07) in SEK SEK52.8
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:QLINES PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:QLINEA Share Price ÷ Book Value per Share (both in SEK)

= 52.8 ÷ 14.88

3.55x

* Primary Listing of Q-linea.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Q-linea is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Q-linea's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Q-linea has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Q-linea expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Q-linea expected to grow at an attractive rate?
  • Unable to compare Q-linea's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Q-linea's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.
  • Q-linea's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:QLINES Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:QLINES Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 40.4%
BATS-CHIXE:QLINES Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 93%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:QLINES Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:QLINES Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 421 -9 -26 1
2021-12-31 181 -64 -123 1
2020-12-31 12 -130 -177 1
2020-04-07
BATS-CHIXE:QLINES Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -170 -177
2019-09-30 1 -155 -155
2019-06-30 2 -151 -149
2019-03-31 1 -138 -141
2018-12-31 1 -123 -128
2018-09-30 2 -106 -111
2017-12-31 2 -63 -68

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Q-linea is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Q-linea's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:QLINES Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Q-linea Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:QLINES Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -1.13 -1.13 -1.13 1.00
2021-12-31 -5.28 -5.28 -5.28 1.00
2020-12-31 -7.63 -7.63 -7.63 1.00
2020-04-07
BATS-CHIXE:QLINES Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -7.74
2019-09-30 -7.23
2019-06-30 -7.68
2019-03-31 -8.10
2018-12-31 -8.82
2018-09-30 -8.39
2017-12-31 -6.50

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Q-linea will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Q-linea's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Q-linea has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Q-linea performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Q-linea's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Q-linea does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Q-linea's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Q-linea's 1-year growth to the GB Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Q-linea's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Q-linea Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:QLINES Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.01 -177.35 147.17
2019-09-30 1.32 -154.77 130.44
2019-06-30 1.54 -149.00 123.62
2019-03-31 1.25 -140.72 115.60
2018-12-31 1.08 -128.35 104.14
2018-09-30 2.39 -110.79 90.70
2017-12-31 1.64 -67.88 57.62
2016-12-31 0.08 -60.09 50.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Q-linea has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Q-linea has efficiently used its assets last year compared to the GB Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Q-linea improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Q-linea's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Q-linea has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Q-linea's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Q-linea's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Q-linea is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Q-linea's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Q-linea's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 324.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Q-linea Company Filings, last reported 3 months ago.

BATS-CHIXE:QLINES Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 340.94 0.71 206.48
2019-09-30 400.25 0.81 230.43
2019-06-30 434.47 0.92 269.46
2019-03-31 477.58 1.02 310.61
2018-12-31 513.46 1.13 504.44
2018-09-30 47.26 13.65 50.28
2017-12-31 1.51 3.00 6.59
2016-12-31 8.46 0.00 7.25
  • Q-linea's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Q-linea's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Q-linea has sufficient cash runway for 1.2 years based on current free cash flow.
  • Q-linea has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 36% each year.
X
Financial health checks
We assess Q-linea's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Q-linea has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Q-linea's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Q-linea dividends. Estimated to be 0% next year.
If you bought SEK2,000 of Q-linea shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Q-linea's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Q-linea's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:QLINES Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:QLINES Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Q-linea has not reported any payouts.
  • Unable to verify if Q-linea's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Q-linea's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Q-linea has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Q-linea's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Q-linea's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Q-linea afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Q-linea has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Q-linea's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jonas Jarvius
COMPENSATION SEK2,066,000
AGE 48
TENURE AS CEO 12.3 years
CEO Bio

Dr. Jonas Jarvius, Ph.D serves as the Chief Executive Officer and President of Q-linea AB. Dr. Jarvius serves as Director at QuiaPEG Pharmaceuticals Holding AB (publ) since 2019. Dr. Jarvius serves as part time scientist at Rudbeck Laboratory Uppsala University. Dr. Jarvius Co-founded Olink AB and Q-linea AB. Dr. Jarvius served as its Deputy Board Member. During his PhD studies Dr. Jarvius focused on cross-disciplinary research at the boundaries of microfluidics and molecular medicine. Dr. Jarvius was one of the inventors of the amplified single molecule detection strategies used in Q-line´s platform for BW-detection. Dr. Jarvius is author of more than 15 articles, published in leading journals such as Nature Biotechnology, Nature Methods, Analytical Chemistry and Nucleic Acids Research. He is the designated inventor of 3 patents.

CEO Compensation
  • Jonas's compensation has increased whilst company is loss making.
  • Jonas's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Q-linea management team in years:

1.5
Average Tenure
55
Average Age
  • The average tenure for the Q-linea management team is less than 2 years, this suggests a new team.
Management Team

Jonas Jarvius

TITLE
CEO & President
COMPENSATION
SEK2M
AGE
48
TENURE
12.3 yrs

Anders Lundin

TITLE
Chief Financial Officer
AGE
55
TENURE
2.3 yrs

Nils Kristensen

TITLE
Chief Operating Officer
AGE
56
TENURE
3.3 yrs

Charlotta Göransson

TITLE
Sales & Marketing Director
AGE
47
TENURE
0.3 yrs

Tiziana Di Martino

TITLE
Chief Medical Officer
TENURE
0.8 yrs

Thomas Fritz

TITLE
Chief Commercial Officer
AGE
55
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Q-linea board of directors in years:

2.3
Average Tenure
65
Average Age
  • The average tenure for the Q-linea board of directors is less than 3 years, this suggests a new board.
Board of Directors

Erika Eriksson

TITLE
Chairperson
AGE
57
TENURE
2.3 yrs

Marianne Hansson

TITLE
Independent Director
COMPENSATION
SEK107K
AGE
56
TENURE
2.3 yrs

Mats Nilsson

TITLE
Director
COMPENSATION
SEK75K
AGE
50
TENURE
12.3 yrs

Hans Johansson

TITLE
Independent Director
COMPENSATION
SEK50K
AGE
65
TENURE
2.3 yrs

Marcus Storch

TITLE
Independent Director
COMPENSATION
SEK75K
AGE
77
TENURE
2.3 yrs

Ulf Landegren

TITLE
Independent Director
COMPENSATION
SEK75K
AGE
67
TENURE
8.3 yrs

Per-Olof Wallström

TITLE
Independent Director
COMPENSATION
SEK90K
AGE
70
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
X
Management checks
We assess Q-linea's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Q-linea has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. It offers inventive systems for in vitro diagnostics for infectious diseases. The company’s principal product candidate is ASTar phenotypic antibiotic susceptibility testing that delivers information on bacterial pathogens and their antibiotic susceptibility for managing sepsis patients. It develops and delivers solutions for healthcare providers to diagnose and treat infectious disease. Q-linea AB (publ) was founded in 2008 and is headquartered in Uppsala, Sweden.

Details
Name: Q-linea AB (publ)
QLINES
Exchange: BATS-CHIXE
Founded: 2008
SEK1,293,132,495
23,009,475
Website: http://www.qlinea.com
Address: Q-linea AB (publ)
Dag Hammarskjölds väg 52 A,
Uppsala,
Uppsala County, 752 37,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM QLINEA Ordinary Shares OMX Nordic Exchange Stockholm SE SEK 07. Dec 2018
DB 3F8 Ordinary Shares Deutsche Boerse AG DE EUR 07. Dec 2018
BATS-CHIXE QLINES Ordinary Shares BATS 'Chi-X Europe' GB SEK 07. Dec 2018
Number of employees
Current staff
Staff numbers
70
Q-linea employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 21:40
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/02/19
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.